Sanofi
SAN
주식 순위
#224
Sanofi is a global healthcare enterprise dedicated to the research,... Sanofi is a global healthcare enterprise dedicated to the research, development, manufacturing, and commercialization of therapeutic solutions across the United States, Europe, and other international markets. Its business is structured into three primary divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment delivers specialized treatments, encompassing human monoclonal antibodies and therapies for a range of conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare disorders, oncology, and rare blood conditions. This division also provides medications for diabetes, cardiovascular health, and a portfolio of established prescription drugs. Through its Vaccines division, Sanofi supplies crucial immunizations, including pediatric vaccines for diseases like poliomyelitis, pertussis, and Hib, alongside adult vaccines addressing influenza, booster needs, meningitis, and those required for travel or endemic regions. The Consumer Healthcare portfolio features over-the-counter remedies for common ailments such as allergies, coughs and colds, and pain relief. It also includes products for liver care, general physical and mental wellness, probiotics, digestive health, and nutritional support. Additionally, this segment offers personal care items like daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema. Sanofi maintains an active pipeline with numerous pharmaceutical products and vaccines currently undergoing various stages of development. The company has forged strategic alliances, including a collaboration with GlaxoSmithKline for the development of a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine aimed at advancing immunology and inflammation knowledge, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company operated as Sanofi-Aventis before rebranding to Sanofi in May 2011.
주가
$83.84
시가총액
$100.45B
변동 (1일)
1.48%
변동 (1년)
-16.74%
국가
FR
거래 Sanofi (SAN)
카테고리
Healthcare
Sanofi (SAN)의 영업이익률
October 2026 기준 영업이익률 TTM: 20.58%
Sanofi의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 20.58%입니다. 2024년 말 기준 영업이익률은 32.63%였습니다.
Sanofi의 영업이익률 기록 (2001 ~ 2026)
매년 말 영업이익률
| 연도 | 영업이익률 | 변화 |
|---|---|---|
| 2026 (TTM) | 20.58% | 0.19% |
| 2025 | 20.54% | -37.05% |
| 2024 | 32.63% | 3.36% |
| 2023 | 31.57% | -3.22% |
| 2022 | 32.62% | 57.28% |
| 2021 | 20.74% | -45.09% |
| 2020 | 37.77% | 365.72% |
| 2019 | 8.11% | -38.14% |
| 2018 | 13.11% | -18.16% |
| 2017 | 16.02% | -14.88% |
| 2016 | 18.82% | 16.68% |
| 2015 | 16.13% | -14.88% |
| 2014 | 18.95% | 19.03% |
| 2013 | 15.92% | -28.19% |
| 2012 | 22.17% | 35.60% |
| 2011 | 16.35% | -12.14% |
| 2010 | 18.61% | -10.10% |
| 2009 | 20.70% | -38.90% |
| 2008 | 33.88% | 67.39% |
| 2007 | 20.24% | 4.17% |
| 2006 | 19.43% | -25.64% |
| 2005 | 26.13% | -1,593.14% |
| 2004 | -1.75% | -104.58% |
| 2003 | 38.21% | 8.89% |
| 2002 | 35.09% | 8.10% |
| 2001 | 32.46% | 0.00% |
유사 기업 또는 경쟁사의 영업이익률
| 회사 | 영업이익률 | 영업이익률 차이 | 국가 |
|---|---|---|---|
| 49.72% | -97.58% |
US
|
|
| 25.70% | -98.75% |
US
|
|
| 29.32% | -98.58% |
US
|
|
| 16.65% | -99.19% |
US
|
|
| 31.92% | -98.45% |
CH
|
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.